Sunvozertinib (Synonyms: DZD9008) |
| Catalog No.GC63521 |
Sunvozertinib(DZD9008)은 강력한 ErbB(EGFR, Her2, 특히 돌연변이 형태) 및 BTK 억제제입니다. Sunvozertinib은 EGFR 엑손 20 NPH 삽입, EGFR 엑손 20 ASV 삽입, EGFR L858R 및 T790M 돌연변이, Her2 Apat14, WOpat1416, WOpat14 EGFR19에 대해 각각 20.4, 20.4, 1.1, 7.5 및 80.4 nM의 IC50을 보여줍니다. 52).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2370013-12-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Sunvozertinib is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52)[1].
Sunvozertinib shows GI50s of 60.4, 83.2, 3.3, 101.3, and 47.1 nM for EGFR exon NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively. Sunvozertinib shows GI50s of 3.2, 5.8, 51.3, and 1983.5 nM for BTK WT OCI-LY-10, BTK WT TMD-8, BTK WT Ri-1, and non-BCR activated DB, respectively[1].Sunvozertinib inhibits p-BTK with IC50 of 1.6 nM[1].
[1]. Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1.
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *